KN
KNSA.US Kiniksa Pharmaceuticals Ltd
- Market cap
- USD 7.57B
- P/E
- 73.0x
- P/B
- 10.67x
- ROE
- 17.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KNSA.US undervalued?
Graham numberThe Graham number of Kiniksa Pharmaceuticals Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kiniksa Pharmaceuticals Ltd fundamental analysis
No fundamental analysis for Kiniksa Pharmaceuticals Ltd yet.
Kiniksa Pharmaceuticals Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, wh…
Full company profileKiniksa Pharmaceuticals Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kiniksa Pharmaceuticals Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 7.70M | 38.5M | 220M | 270M | 423M | 678M | 992M |
| Gross Profit | -22.0K | -28.0K | -286K | -3.28M | -3.81M | 29.4M | 197M | 214M | 362M | 370M | 536M |
| Operating Income | -24.0M | -65.4M | -108M | -170M | -157M | -157M | 9.77M | -25.2M | -45.6M | 77.2M | 148M |
| EBITDA | -24.0M | -65.4M | -108M | -168M | -155M | -154M | 13.4M | -14.3M | -34.5M | 90.4M | 160M |
| Net Income | -24.0M | -64.9M | -103M | -162M | -161M | -158M | 183M | 14.1M | -43.2M | 59.0M | 127M |
| EPS | -0.74 | -2.00 | -3.49 | -2.99 | -2.61 | -2.30 | 2.60 | 0.20 | -0.60 | 0.75 | 1.50 |
| Balance Sheet | |||||||||||
| Total Assets | 56.5M | 47.5M | 322M | 255M | 349M | 233M | 460M | 526M | 581M | 764M | 983M |
| Total Liabilities | 82.2M | 137M | 42.7M | 29.1M | 37.5M | 47.8M | 63.5M | 87.5M | 142M | 196M | 273M |
| Shareholders' Equity | -25.7M | -89.7M | -194M | 225M | 312M | 185M | 396M | 439M | 438M | 568M | 710M |
| Cash & Short-term Investments | 56.0M | 45.6M | 307M | 233M | 323M | 182M | 191M | 206M | 244M | 414M | 569M |
| Total Debt | - | - | - | 2.65M | 6.99M | 6.05M | 5.92M | 12.3M | 9.86M | 9.50M | 7.88M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -21.9M | -50.2M | -81.0M | -158M | -137M | -126M | 5.81M | 13.3M | 25.7M | 25.7M | 193M |
| Capital Expenditure | 3.00K | 69.0K | 5.29M | 3.20M | 283K | 20.4M | 105K | 130K | 277K | 277K | 1.34M |
| Free Cash Flow | -21.9M | -50.3M | -86.3M | -162M | -137M | -147M | 5.70M | 13.2M | 25.4M | 25.4M | 192M |
| Ratios | |||||||||||
| ROE | - | - | - | -71.8% | -51.7% | -85.3% | 46.3% | 3.2% | -9.9% | 10.4% | 17.9% |
| ROA | -42.5% | -136.6% | -32.1% | -63.6% | -46.2% | -67.8% | 39.9% | 2.7% | -7.4% | 7.7% | 12.9% |
| Net Profit Margin | - | - | - | - | -2,094.8% | -409.7% | 83.3% | 5.2% | -10.2% | 8.7% | 12.8% |
| Debt to Equity | - | - | - | 0.01x | 0.02x | 0.03x | 0.01x | 0.03x | 0.02x | 0.02x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kiniksa Pharmaceuticals Ltd dividends
Kiniksa Pharmaceuticals Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:1 on Jun 28, 2024.
Who owns Kiniksa Pharmaceuticals Ltd
- Insiders 4.21%
- Institutions 95.79%
- Public & others 0.00%
- Shares outstanding 48.8M
- Free float 40.6M
Top funds holding KNSA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.39M | 1.77% | +5.26% | Sep 2026 |
| iShares Russell 2000 ETF | 1.16M | 1.47% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 979K | 1.25% | +2.14% | Sep 2026 |
| Fidelity Select Health Care | 970K | 1.23% | +5.43% | Aug 2026 |
| Strategic Advisers Fidelity US TtlStk | 762K | 0.97% | +12.67% | Sep 2026 |
| Fidelity Select Biotechnology | 638K | 0.81% | 0.00% | Aug 2026 |
| Pictet-Biotech P USD | 588K | 0.75% | +47.32% | Jul 2026 |
| Fidelity Small Cap Growth | 581K | 0.74% | 0.00% | Aug 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 545K | 0.69% | -1.26% | Sep 2026 |
| Fidelity Advisor Health Care I | 500K | 0.64% | +5.49% | Sep 2026 |
| Fidelity Small Cap Index | 464K | 0.59% | +0.16% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 428K | 0.55% | -0.38% | Oct 2026 |
| Oberweis Micro-Cap | 390K | 0.50% | +27.72% | Jun 2026 |
| Fidelity Advisor Biotechnology I | 385K | 0.49% | -7.76% | Sep 2026 |
| Fidelity Stock Selector Small Cap | 364K | 0.46% | +32.60% | Aug 2026 |
| T. Rowe Price Health Sciences | 329K | 0.42% | -16.62% | Sep 2026 |
| Victory Trivalent International Sm-Cp I | 321K | 0.41% | -3.46% | Sep 2026 |
| Fidelity Small Cap Growth K6 | 292K | 0.37% | 0.00% | Aug 2026 |
| Heptagon Driehaus US Micro Cap Eq C$ Acc | 283K | 0.36% | 0.00% | Sep 2026 |
| MFS New Discovery I | 276K | 0.35% | -7.55% | Sep 2026 |
Top institutions holding KNSA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 6.97M | 8.87% | +2.16% | Jun 2026 |
| Rubric Capital Management LP | 4.00M | 5.09% | +6.66% | Jun 2026 |
| Baker Bros Advisors LP | 2.83M | 3.61% | +0.30% | Jun 2026 |
| BlackRock Inc | 2.74M | 3.49% | +462.85% | Jun 2026 |
| TANG CAPITAL MANAGEMENT LLC | 2.26M | 2.88% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.91M | 2.43% | +8.21% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.36M | 1.73% | +2.08% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.01M | 1.29% | +1.34% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 958K | 1.22% | +7.26% | Jun 2026 |
| Spruce Street Capital LP | 918K | 1.17% | +20.63% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 843K | 1.07% | -3.62% | Sep 2026 |
| Amvescap Plc. | 773K | 0.98% | +2,694.35% | Jun 2026 |
| Driehaus Capital Management LLC | 718K | 0.91% | +17.47% | Jun 2026 |
| State Street Corp | 704K | 0.90% | +818.92% | Jun 2026 |
| Point72 Asset Management, L.P. | 659K | 0.84% | +2.89% | Jun 2026 |
| Rice Hall James & Associates, LLC | 625K | 0.80% | +2.71% | Jun 2026 |
| Pictet Asset Manangement SA | 609K | 0.77% | -2.35% | Jun 2026 |
| Geode Capital Management, LLC | 604K | 0.77% | +1,263.22% | Jun 2026 |
| Jupiter Topco LLC | 586K | 0.75% | 0.00% | Jun 2026 |
| Connor Clark & Lunn Inv Mgmt Ltd | 573K | 0.73% | -11.86% | Jun 2026 |
Kiniksa Pharmaceuticals Ltd company profile
- Company name
- Kiniksa Pharmaceuticals Ltd
- Ticker
- KNSA.US
- ISIN
- GB00BRXB0C07
- Exchange
- USA Stocks
- Listed since
- May 24, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 366
- Fiscal year end
- December
- Address
- 105 Piccadilly, London, United Kingdom, W1J 7NJ
- Phone
- 44 78 1431 9100
- Website
- kiniksa.com
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Kiniksa Pharmaceuticals Ltd management
10- Mr. Sanjiv K. PatelCEO & Chairman of the Board · born 1969
- Mr. Ross Michael MoatPresident, Executive VP, COO & Principal Operating Officer · born 1980
- Mr. Mark A. Ragosa C.F.A.Executive VP & CFO · born 1974
- Dr. John F. Paolini FACC, M.D., Ph.D.Executive VP & Chief Medical Officer · born 1965
- Mr. Eben TessariConsultant · born 1982
- Mr. Michael R. Megna CPASenior VP & Chief Accounting Officer · born 1971
- Ms. Mei JangSenior VP & Chief Technical Officer
- Mr. Jonathan KirshenbaumInvestor Relations Officer
- Mr. Douglas J. BarrySenior VP, Chief Legal Officer & Secretary
- Ms. Martina Struck Ph.D.Senior VP & Chief Regulatory Officer